1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. LAVA THERAPEUTICS NV

LAVA Therapeutics NV

XNAS: LVTX

Download real time

1.30 0.00 (0.00%)

69.12% Fall from 52W High

22,117 XNAS Volume

XNAS 21 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
12S
7W
3O
0T
34.2

Market Cap

Below industry Median
-1.2

PE TTM

Negative PE TTM
0

PEG TTM

1

Price to Book

Below industry Median
-0.3

Beta 1Year

Very Low volatility
Board Meeting
The next board meeting for LAVA Therapeutics NV is on 27 Mar 2025 for the purpose of LAVA Therapeutics NV Annual Report for 2024 See details


Insider Trading disclosures for LAVA Therapeutics NV

The latest disclosure was made by Peter A. Kiener in LAVA Therapeutics NV where a trade of 33,390 Common Shares (Right to Buy) done was reported to US exchanges on Feb. 13, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Peter A. Kiener Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2025 33,390 33,390 - - Common Shares (Right to Buy)
Fred M. Powell Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2025 124,700 124,700 - - Share Options (Right to Buy)
Karen J. Wilson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2025 33,390 33,390 - - Common Shares (Right to Buy)
Kapil Dhingra Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2025 33,390 33,390 - - Common Shares (Right to Buy)
Charles Morris Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2025 130,850 130,850 - - Share Options (Right to Buy)
Stephen A. Hurly Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2025 335,100 335,100 - - Share Options (Right to Buy)
Jay T. Backstrom Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2025 33,390 33,390 - - Common Shares (Right to Buy)
Mary E. Wadlinger Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2025 33,390 33,390 - - Common Shares (Right to Buy)
Christy J. Oliger Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2025 33,390 33,390 - - Common Shares (Right to Buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters